UniProtKB/Swiss-Prot P15153: Variant p.Glu62Lys

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 62 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Glutamate (E) to Lysine (K) at position 62 (E62K, p.Glu62Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from medium size and acidic (E) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In IMD73B; gain-of-function variant; exhibits impaired GAP-mediated GTP hydrolysis, resulting in sustained GTP association and prolonged RAC2-driven activation of downstream effectors; when transfected into cells, shows increased basal reactive oxygen species production following stimulation by PMA compared to cells transfected with wild-type; increased interaction with PAK1, compared to wild-type. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs1555908409 [ dbSNP | Ensembl ]

Sequence information

Variant position: 62 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 192 The length of the canonical sequence.
Location on the sequence: ANVMVDSKPVNLGLWDTAGQ E DYDRLRPLSYPQTDVFLICF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 189	Ras-related C3 botulinum toxin substrate 2
Helix	62 – 64

Literature citations

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects.
Hsu A.P.; Donko A.; Arrington M.E.; Swamydas M.; Fink D.; Das A.; Escobedo O.; Bonagura V.; Szabolcs P.; Steinberg H.N.; Bergerson J.; Skoskiewicz A.; Makhija M.; Davis J.; Foruraghi L.; Palmer C.; Fuleihan R.L.; Church J.A.; Bhandoola A.; Lionakis M.S.; Campbell S.; Leto T.L.; Kuhns D.B.; Holland S.M.;
Blood 133:1977-1988(2019)
Cited for: INVOLVEMENT IN IMD73B; VARIANT IMD73B LYS-62; CHARACTERIZATION OF VARIANT IMD73B LYS-62; FUNCTION; INTERACTION WITH PAK1; A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease.
Smits B.M.; Lelieveld P.H.C.; Ververs F.A.; Turkenburg M.; de Koning C.; van Dijk M.; Leavis H.L.; Boelens J.J.; Lindemans C.A.; Bloem A.C.; van de Corput L.; van Montfrans J.; Nierkens S.; van Gijn M.E.; Geerke D.P.; Waterham H.R.; Koenderman L.; Boes M.;
Clin. Immunol. 212:108248-108248(2020)
Cited for: INVOLVEMENT IN IMD73B; VARIANT IMD73B LYS-62; CHARACTERIZATION OF VARIANT IMD73B LYS-62;